Key Takeaway: Omeros Corporation announced that the CMS has granted New Technology Add-On Payment status to YARTEMLEA (narsoplimab-wuug) for the treatment of thrombotic microangiopathy associated with hematopoietic stem cell transplants. This status will take effect on October 1, 2026, allowing eligible hospitals to receive additional payments for treating Medicare patients with this therapy.
Price reaction · baseline $11.84 (2026-07-31 close) · hit pre-market · clean, no other OMER news in the window
day 0 close · peak
+6.1%
Market Sentiment Analysis
POSITIVE FACTORS
CMS granted NTAP status for YARTEMLEA, enhancing its market access.
This approval supports hospitals treating Medicare patients.
YARTEMLEA addresses a critical condition, TA-TMA, improving patient care.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLEA® (narsoplimab-wuug) under the Fiscal Year (FY) 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule. Beginning October 1, 2026, eligible hospitals treating Medicare patients with YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) wi
Frequently Asked Questions
What is YARTEMLEA used for?
YARTEMLEA is used to treat thrombotic microangiopathy associated with hematopoietic stem cell transplants.
When does the NTAP status for YARTEMLEA take effect?
The NTAP status for YARTEMLEA will take effect on October 1, 2026.
Who benefits from the NTAP status?
Eligible hospitals treating Medicare patients with YARTEMLEA will benefit from the NTAP status.
What does NTAP status mean?
NTAP status allows hospitals to receive additional payments for new technologies.